Marketing

Abstract: The European Commission has approved Pfizer`s first-of-its-kind oral Janus kinase (JAK) inhibitor  XELJANZ® (Tofacitinib) 5 mg twice daily for the treatment…

SYNOPSIS: VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s…

KEYPOINTS: AbbVie announces that the European Commission (EC) has approved SKYRIZI (Risankizumab, 150 mg, subcutaneous injection at week 0, week 4, and…